More on NVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $154.14 |
|
|||
| Open | $157.50 | ||||
| 52 Wk High | $89.15 | ||||
| 52 Wk Low | $69.84 | ||||
| Day High | $160.57 | ||||
| Day Low | $157.00 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,588,016 | ||||
- Novartis wins EU approval for SMA gene therapy in older patients
- Increasing unusual put volume: STRC EWA HTZ EIX NVS SITM WEN STWD VSH PENG ZIM
- Barclays Reiterates Equalweight Rating on Novartis (NOVN:SW) (NVS)
- Novartis (NOVN:SW) (NVS) PT Raised to CHF140 at Deutsche Bank
- The Quest to Repair What Multiple Sclerosis Takes Away
- Antares Therapeutics and Novartis team up on cancer drug discovery
- German government to drop variable drug discounting plans - Reuters
- Novartis drug shows efficacy in chronic urticaria trial
- Form 6-K NOVARTIS AG For: Jun 11
- Novartis reports positive biomarker results for experimental FSHD treatment
Entities mentioned with NVS
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
